Evox has created a comprehensive intellectual property estate dominating the exosome therapeutics landscape. Our proprietary DeliverEX® platform enables loading of exosomes with diverse drug cargos, leverages the unique tissue targeting properties of exosomes, and supports proprietary manufacturing and purification methods for advanced exosome therapeutics.
Through partnering with leading organisations, we seek to maximise the potential of exosome therapeutics, either by solving delivery and development challenges for partners using our proprietary DeliverEX® platform or to accelerate the development of our in-house rare disease assets with the aid of outside expertise and capabilities.
Partnering discussions fall into two areas:
Platform partnering opportunities
Pipeline partnering opportunities
We have a relentless commitment to progressing our rare disease programs to impact patients’ lives and we are always on the lookout for partners who can help us achieve this aim.
Having a network of strong partnerships is a cornerstone of our success. We are driven to solve challenges together with our research partners and we see technical and medical hurdles as an opportunity to transform the treatment of severe illnesses.